Exploring the impact of dexamethasone on gene regulation in myeloma cells.


Journal

Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869

Informations de publication

Date de publication:
09 2023
Historique:
received: 01 06 2023
revised: 23 06 2023
accepted: 26 06 2023
medline: 3 8 2023
pubmed: 1 8 2023
entrez: 31 7 2023
Statut: epublish

Résumé

Among glucocorticoids (GCs), dexamethasone (Dex) is widely used in treatment of multiple myelomas. However, despite a definite benefit, all patients relapse. Moreover, the molecular basis of glucocorticoid efficacy remains elusive. To determine genomic response to Dex in myeloma cells, we generated bulk and single-cell multi-omics data and high-resolution contact maps of active enhancers and target genes. We show that a minority of glucocorticoid receptor-binding sites are associated with enhancer activity gains, increased interaction loops, and transcriptional activity. We identified and characterized a predominant enhancer enriched in cohesin (RAD21) and more accessible upon Dex exposure. Analysis of four gene-specific networks revealed the importance of the CTCF-cohesin couple and the synchronization of regulatory sequence openings for efficient transcription in response to Dex. Notably, these epigenomic changes are associated with cell-to-cell transcriptional heterogeneity, in particular, lineage-specific genes. As consequences,

Identifiants

pubmed: 37524526
pii: 6/9/e202302195
doi: 10.26508/lsa.202302195
pmc: PMC10390781
pii:
doi:

Substances chimiques

Dexamethasone 7S5I7G3JQL
Glucocorticoids 0
Receptors, Glucocorticoid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023 Bessonneau-Gaborit et al.

Références

Cell. 2018 May 17;173(5):1165-1178.e20
pubmed: 29706548
Nature. 2008 Jul 10;454(7201):226-31
pubmed: 18568025
Science. 2014 Jan 17;343(6168):301-5
pubmed: 24292625
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
Cell Rep. 2015 Jul 28;12(4):622-35
pubmed: 26190113
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Immunity. 2017 Aug 15;47(2):298-309.e5
pubmed: 28801231
Cell. 2014 Oct 9;159(2):358-73
pubmed: 25303530
Clin Cancer Res. 2012 Oct 1;18(19):5499-506
pubmed: 22855579
Nat Methods. 2018 Feb 28;15(3):155-156
pubmed: 29489746
Mol Cell. 2018 Sep 6;71(5):858-871.e8
pubmed: 30078726
Genome Biol. 2015 Dec 01;16:264
pubmed: 26619937
Nat Genet. 2011 Mar;43(3):264-8
pubmed: 21258342
Nat Genet. 2017 Nov;49(11):1602-1612
pubmed: 28945252
Genome Biol. 2009;10(3):R25
pubmed: 19261174
N Engl J Med. 2022 Aug 11;387(6):495-505
pubmed: 35661166
Cell Syst. 2018 Aug 22;7(2):146-160.e7
pubmed: 30031775
Genome Res. 2019 Aug;29(8):1223-1234
pubmed: 31337711
EMBO J. 2013 May 29;32(11):1568-83
pubmed: 23665916
Mol Cell. 2011 Jul 8;43(1):145-55
pubmed: 21726817
EMBO J. 2011 Jun 24;30(15):3028-39
pubmed: 21701563
Cancer Cell. 2018 Dec 10;34(6):906-921.e8
pubmed: 30537513
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nat Methods. 2016 Nov;13(11):919-922
pubmed: 27643841
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Res. 2018 Sep;28(9):1272-1284
pubmed: 30097539
Nat Protoc. 2012 Mar 01;7(3):562-78
pubmed: 22383036
Nat Commun. 2018 Mar 5;9(1):943
pubmed: 29507293
Nucleic Acids Res. 2015 Jul 1;43(W1):W39-49
pubmed: 25953851
Blood. 2018 May 10;131(19):2138-2150
pubmed: 29519805
Cell. 2013 Nov 7;155(4):934-47
pubmed: 24119843
Nat Genet. 2016 Oct;48(10):1193-203
pubmed: 27526324
Clin Cancer Res. 2019 Aug 15;25(16):4907-4916
pubmed: 31142508
BMC Genomics. 2016 Mar 22;17:252
pubmed: 27004515
Nat Biotechnol. 2019 Aug;37(8):925-936
pubmed: 31375813
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
Nat Biotechnol. 2010 Aug;28(8):817-25
pubmed: 20657582
Curr Protoc Mol Biol. 2015 Jan 05;109:21.29.1-21.29.9
pubmed: 25559105
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Genome Res. 2015 Jun;25(6):845-57
pubmed: 25677181
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Commun Biol. 2020 Mar 13;3(1):126
pubmed: 32170217
Nat Commun. 2022 Sep 6;13(1):5253
pubmed: 36068241
Bioinformatics. 2009 May 1;25(9):1105-11
pubmed: 19289445
Mol Cell Biol. 2002 May;22(10):3255-63
pubmed: 11971959
Nat Commun. 2019 Apr 23;10(1):1874
pubmed: 31015400
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Nucleic Acids Res. 2018 Jan 9;46(1):203-214
pubmed: 29126175
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Nat Methods. 2012 Feb 28;9(3):215-6
pubmed: 22373907
Mol Cell Biol. 2008 Feb;28(4):1413-26
pubmed: 18086889
Blood. 2007 Apr 1;109(7):2708-17
pubmed: 17119115
Sci Rep. 2019 Jun 27;9(1):9354
pubmed: 31249361
Nat Biotechnol. 2010 May;28(5):495-501
pubmed: 20436461
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W187-91
pubmed: 24799436
Sci Data. 2016 Dec 20;3:160109
pubmed: 27996962
Sci Data. 2019 May 20;6(1):65
pubmed: 31110271
Nat Commun. 2022 Apr 19;13(1):2139
pubmed: 35440598
Cell Rep. 2019 Nov 26;29(9):2634-2645.e5
pubmed: 31775034
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Genome Res. 2009 Dec;19(12):2163-71
pubmed: 19801529
Genome Biol. 2015 Dec 01;16:259
pubmed: 26619908
Sci Adv. 2022 Apr;8(13):eabj8360
pubmed: 35353576
Cell. 2016 Aug 25;166(5):1269-1281.e19
pubmed: 27565349
Nat Commun. 2017 Jan 16;8:14049
pubmed: 28091601
Oncotarget. 2015 Sep 29;6(29):26922-34
pubmed: 26323097
Cancer Cell. 2014 Dec 8;26(6):813-825
pubmed: 25490447
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Science. 2018 Nov 2;362(6414):
pubmed: 30385546
Mol Cell Biol. 2004 Apr;24(8):3347-58
pubmed: 15060156
Nat Biotechnol. 2015 May;33(5):495-502
pubmed: 25867923

Auteurs

Victor Bessonneau-Gaborit (V)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France.
Centre Hospitalier Universitaire, Nantes, France.

Jonathan Cruard (J)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France.

Catherine Guerin-Charbonnel (C)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France.
Institut de Cancérologie de l'Ouest, Nantes, France.

Jennifer Derrien (J)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France.

Jean-Baptiste Alberge (JB)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France.

Elise Douillard (E)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France.
Centre Hospitalier Universitaire, Nantes, France.

Magali Devic (M)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France.
Centre Hospitalier Universitaire, Nantes, France.

Sophie Deshayes (S)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France.

Loïc Campion (L)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France.
Institut de Cancérologie de l'Ouest, Nantes, France.

Frank Westermann (F)

Hopp Children's Cancer Center Heidelberg, KITZ, Heidelberg, Germany.
Division of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Germany.

Phillipe Moreau (P)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France.
Centre Hospitalier Universitaire, Nantes, France.

Carl Herrmann (C)

Health Data Science Unit, Medical Faculty Heidelberg and BioQuant, Heidelberg, Germany.

Jérémie Bourdon (J)

Université de Nantes, LS2N, CNRS, Nantes, France.

Florence Magrangeas (F)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France florence.magrangeas@chu-nantes.fr.
Centre Hospitalier Universitaire, Nantes, France.

Stéphane Minvielle (S)

Université de Nantes, CNRS, INSERM, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, France stephane.minvielle@univ-nantes.fr.
Centre Hospitalier Universitaire, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH